Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Silexion TherapeuticsSLXN +0.73%13 Pretax Margin % is % as of Jun. 2026. GuruFocus rates SLXN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Silexion Therapeutics ranks worse than 105820% on this metric.
The historical rank and industry rank for Silexion Therapeutics's Pretax Margin % or its related term are showing as below:
SLXN's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -80.02 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Silexion Therapeutics Pretax Margin % Related Terms
Silexion Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Silexion Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLXN vs DCOY, VRAX, PTIX: Pretax Margin % Comparison
For the Biotechnology subindustry, Silexion Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silexion Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Silexion Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silexion Therapeutics (SLXN) has a Pretax Margin % of % as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Silexion Therapeutics and its competitors. According to the industry distribution chart, Silexion Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Silexion Therapeutics' Pretax Margin % too high?
Silexion Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Silexion Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silexion Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Silexion Therapeutics' Pretax Margin % compare to DCOY and VRAX?
According to the Biotechnology industry distribution chart, Silexion Therapeutics ranks #999999 out of 945 companies for Pretax Margin %. This places Silexion Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Silexion Therapeutics and its competitors. Silexion Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silexion Therapeutics stock overvalued right now?
Silexion Therapeutics (SLXN) has a current Pretax Margin % of %. The current Pretax Margin % is %. Silexion Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Silexion Therapeutics (SLXN), the current Pretax Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
13GF Score
Get the complete analysis for SLXN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLXN has been successfully added to your 
